Therefore, we believe that more specific and more potent STAT5 blockers may be a reasonable approach to target MPN cells, and additional drugs or drug combinations, as proposed by Bar-Natan et al. [53] and others, may be required to elicit optimal anti-neoplastic or even curative effects. The gene discussed is STAT5B; the disease is myeloproliferative neoplasm.